Advertisements

Pernazinum

Quick links to important sections

Pernazinum

Advertisements
Advertisements

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Pernazinum

Property Description
Active ingredient Perazine (Perazine Dimalonate)
Forms Tablets, liquid solutions
Pharmacological class Typical Antipsychotic, Phenothiazine derivative
General purpose Stabilizing disturbed thought and behavior
Origin Synthetic

Definition, Class, and Composition

Pernazinum is a distinct pharmaceutical preparation defined by its sole active ingredient, Perazine, which is officially classified as a Typical Antipsychotic (First-Generation). Perazine is a synthetic chemical compound derived from the phenothiazine structure. This classification places it within the established psycholeptic drug group, and its specific structure includes a piperazine side chain, distinguishing it within the phenothiazine family. The consistent use and study of this compound have led to its clinical recognition as an agent for modulating central nervous system function.

Active Ingredient, Form, and General Purpose

The medication functions as a single-active-ingredient product, with its therapeutic effects stemming entirely from Perazine, typically prepared as the salt Perazine Dimalonate. Pernazinum is available for oral intake, provided in the form of both tablets and a liquid solution, allowing for flexible use in certain patient groups. Its general purpose is to provide pharmacological support for stabilizing profoundly disturbed thought patterns and emotional states. The utility of Perazine in managing severe agitation and psychosis relates to its role in helping to mitigate emotional distress and supporting overall behavioral regulation.

Pharmacological Context

Perazine's primary mechanism is based on its action as a central dopamine D2 receptor antagonist. This fundamental action is understood in pharmacology and serves as the core basis for the drug's effectiveness. The application of this drug in managing acute psychotic episodes and chronic thought disorders underscores its established place in psychopharmacology, distinguishing it as a tool for regulating severe neurochemical imbalances.

Advertisements

What side effects are possible with Pernazinum?

Pernazinum's safety profile, consistent with its classification as a phenothiazine derivative, is organized by regulatory documents according to affected System-Organ Classes and specific risk categories. Adverse reactions are grouped across the Nervous System, Cardiovascular System, Blood and Lymphatic System, and Endocrine System.

A key focus in the official labeling is on Movement-Related Side Effects, including Extrapyramidal Symptoms (EPS), such as tremor and rigidity, and Tardive Dyskinesia (TD), a potentially irreversible condition associated with prolonged administration. Sedation and dizziness may be more pronounced during the initial phase of therapy.

Several Serious Adverse Syndromes are officially documented. These include Neuroleptic Malignant Syndrome (NMS), a potentially fatal complex, and severe Hematological Risks such as Agranulocytosis. The labeling also notes Cardiovascular Risks, including QT prolongation, which may lead to serious ventricular arrhythmias, and the risk of significant hypotension.

Population-Specific Safety Warnings highlight specific risks in certain patient groups. A mandatory warning exists for Older Adults with Dementia-Related Psychosis, citing an increased risk of death from cardiovascular or infectious causes. Additionally, Neonates exposed during the third trimester of pregnancy are at risk for withdrawal and extrapyramidal symptoms following delivery.

Safety-related restrictions emphasize that the medicine is contraindicated in conditions such as comatose states, known phenothiazine hypersensitivity, or existing blood dyscrasias.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation on Perazine (Pernazinum) overdose profiles highlights severe, potentially life-threatening manifestations requiring immediate emergency intervention.

Documented Overdose Presentations

Overdose presentations are primarily characterized by Central Nervous System (CNS) depression, which may range from drowsiness and stupor to deep coma. Other documented neurological signs include convulsions (seizures) and severe extrapyramidal symptoms (EPS), such as involuntary movements and muscle rigidity. Cardiovascular and autonomic effects are critical, including severe hypotension (low blood pressure) and potential for life-threatening cardiac arrhythmias and EKG changes.

Severe Outcomes and Emergency Actions

Severe outcomes documented in the regulatory profile include Neuroleptic Malignant Syndrome (NMS) and circulatory shock. Management is strictly symptomatic and supportive, as no known specific antidote is documented. Regulatory agencies mandate that immediate medical attention must be sought, and emergency services must be contacted immediately upon any suspicion of overdose. Hospital monitoring, including continuous ECG monitoring, is required.

Population Considerations

Official labeling notes that children may be more susceptible to experiencing convulsive seizures. Elderly patients are documented as being particularly sensitive to hypotensive and extrapyramidal effects.

Advertisements

Therapeutic Uses of Pernazinum

What Pernazinum Treats: Main Uses and Benefits

Pernazinum (Perazine) is commonly used within psychiatric contexts, and may be part of symptomatic management and assists with maintaining functional stability across conditions defined by severe disturbances in thought, perception, and emotional regulation. It is considered relevant in clinical settings that involve acute or unstable symptom patterns and may assist with functional stability in chronic disorders, particularly for use in treating schizophrenia and related psychoses.

Symptomatic Relief and Stabilization

This medication is applied across therapeutic domains where additional symptomatic support is needed. It is applied in addressing symptom clusters that may become intense or disruptive, such as hallucinations, delusions, and disorganized thought patterns. It also plays a role in managing episodes of severe anxiety and psychomotor agitation, which frequently accompany these conditions. This is often used during phases when symptoms become more noticeable.

When applied appropriately, the medication may assist with maintaining functional stability and contributes to improved comfort during periods of heightened symptoms.

The medication is generally used to help with a brief listing of indications including psychotic disorders, schizophrenia, and severe agitated states.


Quick Fact: Support for Disturbed Thought and Agitation

Pernazinum assists with maintaining functional stability and contributes to easing the overall symptom load, helping patients cope more steadily with symptom fluctuations.

Advertisements

Eligibility and Restrictions for Use

Pernazinum (Perazine) eligibility is strictly defined by regulatory guidelines concerning the patient's age and clinical status. The medicine is generally approved for use in adults for its labeled indications.

Contraindications and Absolute Exclusions

Use of Pernazinum is absolutely contraindicated in patients with a known hypersensitivity to the phenothiazine class, existing blood dyscrasias or bone marrow depression, and those in comatose states. The medicine is also forbidden for patients with severe cardiovascular disorders, specific forms of subcortical brain damage, and is contraindicated during the third trimester of pregnancy.

Age and Health Restrictions

Regulatory agencies state that the medicine is not recommended or contraindicated for children under 12 years of age. For older adults, use is forbidden in those with dementia-related psychosis due to increased risk.

Use requires restriction or caution in patients with severe hepatic (liver) impairment and renal (kidney) insufficiency. Additional caution is mandated for those with epilepsy or a predisposition to seizures, Parkinson's disease, narrow-angle glaucoma, and prostatic hypertrophy. The medicine is not recommended while breastfeeding as the drug may be excreted in breast milk.

Advertisements

What should I know about interactions with other medicines?

Pernazinum (Perazine) has documented interaction patterns that necessitate specific restrictions or cautions, as defined by government regulatory agencies. These interactions involve co-administered medicinal products, enzymes responsible for drug metabolism, and certain consumer substances.

Interaction Category Interacting Substances / Restrictions Formal Outcome
Contraindicated Combinations Alcohol (Ethanol), Central Nervous System (CNS) Depressants (in large doses) Prohibited due to the risk of severe additive CNS depression and hypotension.
Pharmacodynamic Effects Anticholinergic drugs Results in additive effects, increasing the risk of peripheral and central anticholinergic symptoms.
Restricted Agent Use Epinephrine (Adrenaline) Its use is restricted to treat hypotension, as Perazine may block its action and paradoxically worsen low blood pressure.

Exposure-Modifying Interactions

Co-administration with certain substances alters the systemic exposure of Perazine via pharmacokinetic mechanisms. CYP2D6 Inhibitors (e.g., specific SSRIs) are documented to increase the plasma concentration of Perazine by reducing its metabolic clearance. Conversely, tobacco smoking acts as a documented lifestyle interaction that increases the drug's clearance, potentially leading to reduced systemic exposure. Furthermore, Perazine itself is known to be a potent CYP1A2 inhibitor, which can increase the exposure of co-administered medicines that are metabolized by that enzyme. There are no timing-based separation requirements documented in official regulatory labels.

Advertisements

Mechanism of Action

Pernazinum primarily acts within the central nervous system through receptor-mediated signaling modulation. Its core mechanism engages multiple neurotransmitter systems, resulting in the alteration of enhanced physiological activity.

Dopamine Receptor Antagonism

Pernazinum exerts its central effect by blocking dopamine D2 receptors in key brain regions like the limbic system. This primary mechanistic action suppresses signaling sequences associated with heightened physiological and behavioral arousal, thereby modulating signal transduction within specific neural pathways.

Serotonin and Adrenergic Modulation

The drug further modifies systemic physiological outcomes by acting as an antagonist at other receptor sites, including serotonin (5-HT2) receptors and alpha-1 adrenergic receptors.

Regulation of Dysregulated Signaling

The multi-receptor interaction restricts the influence of elevated mediator signaling. By engaging mechanisms that regulate overactive or dysregulated processes across dopaminergic, serotonergic, and adrenergic systems, Pernazinum alters physiological parameters and influences the maintenance of the activity profile within affected neurological pathways.

Advertisements

Dosage and Administration Information

Pernazinum (Perazine) is an orally administered phenothiazine derivative. The established usage protocol involves highly individualized dosing and careful, gradual adjustment under medical guidance.


Administration and Dosing Principles

Administration Route and Forms

The route of administration for Pernazinum is oral intake. The medication is typically available as immediate-release tablets (in strengths such as 25 mg, 50 mg, and 100 mg) and as an oral solution or syrup, which allows for precise measurement and flexible administration.

Dosing Schedule and Timing

Treatment begins with a low initial dose that is slowly titrated (increased) over time to find the effective maintenance level. The total daily dose is typically administered in divided doses to maintain stable drug levels. Because of the medication's properties, the largest portion of the daily dose is often scheduled for administration in the evening or at bedtime. The maximum daily dose generally does not exceed 600 mg for typical adult use.


Population and Procedural Rules

Specific dose modifications are utilized for certain populations. For older adults, treatment starts with a significantly reduced starting dose. The dose is also reduced accordingly for patients with hepatic impairment (liver function disorders). The medication can generally be taken without regard to food.

Long-term use involves maintaining stability at the minimum effective dose. If treatment is to be discontinued, established protocols involve lowering the dose gradually (tapered) over a controlled period to complete the course of therapy.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Pernazinum


Evidence for use in Schizophrenia and Related Psychoses

Pernazinum (Perazine) was studied for its use in exploring how symptoms change over time in schizophrenia and related thought disorders. The body of research primarily includes a limited number of short-term Randomized Controlled Trials (RCTs) and systematic reviews and meta-analyses that have examined its use against a placebo or against other existing antipsychotic medications.

Research examined short-term changes in adults diagnosed with these conditions. The main outcomes focused on measurements related to overall clinical state and monitoring scores on standardized psychiatric scales. Studies also recorded the rates of participants who discontinued the trial, which provides context on adherence and other aspects observed in the controlled setting.

Findings describe patterns observed in the studies over short time intervals. Because of the limited number of studies and their small participant numbers, the evidence quality varies across studies, and the certainty about the overall findings remains low.


Evidence for use in Severe Agitated States

The research exploring the use of Pernazinum for severe agitated states was evaluated in studies of acute psychotic episodes, where agitation is a common feature. Formal, dedicated RCTs specifically targeting only agitation as an isolated problem are sparse.

These studies monitored outcomes related to outcomes reflecting daily functioning or activity level, focusing on global functional outcomes during the initial, acute phase of treatment. The evidence contributes to understanding symptom patterns in settings with varying symptom burdens.


Research Gaps and Uncertainty

Most of the available randomized evidence for Pernazinum focuses on research exploring short-term symptom changes. Consequently, long-term effects are not fully established, and there is limited information for long-term outcomes regarding the durability of any observed response.

In addition to the lack of long-term data, data for certain groups remain insufficient. Research exploring its use in older adults or patients with comorbidities (other concurrent health conditions) is not extensively characterized in the primary systematic reviews, meaning results apply only to the populations studied in the original trials.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Pernazinum (FAQ)


Q: How quickly does Pernazinum start working after taking it?

Regulatory documents for similar medications in the same drug class suggest that some initial effects may begin within a relatively short period, such as 10 to 20 minutes after taking certain oral forms. The overall therapeutic effect and duration can vary between individuals and depending on the exact formulation of the medicine.


Q: Can Pernazinum affect my ability to drive?

Official product information includes a specific warning that the medicine may cause central nervous system side effects, such as sedation and dizziness. Official warnings state that caution should be exercised when operating vehicles or heavy machinery, particularly when treatment is first started or the dose is adjusted.


Q: Is Pernazinum safe to use during pregnancy, according to official sources?

Official labeling states the medicine is absolutely contraindicated, or forbidden, during the third trimester of pregnancy. This is due to documented risks of withdrawal and movement-related symptoms in the newborn after delivery. Regulatory documents indicate that use during the first and second trimesters is only considered after medical assessment.


Q: How long does the effect of one dose of Pernazinum typically last?

Official dosing guidelines generally require the total daily amount to be taken in divided doses (several times throughout the day) to help maintain stable drug levels. While the exact duration of a single dose's therapeutic effect varies, similar medications may provide effect for several hours.


Q: What do official documents say about combining Pernazinum with alcohol?

Regulatory documents explicitly state that combining Pernazinum with alcohol is stated as a contraindicated combination (forbidden). This restriction is in place due to the serious risk of severe additive central nervous system depression and dangerously low blood pressure (hypotension).


Q: What is the safety classification of Pernazinum for breastfeeding mothers?

Official guidance states the medicine is generally not recommended while breastfeeding. This is because the drug's active ingredients may be excreted in breast milk.


Q: What happens if I miss a dose of Pernazinum?

Official patient information describes a process where the missed dose is taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the regulatory process indicates skipping the dose to avoid taking a double amount.


Q: Is Pernazinum a controlled substance?

Pernazinum (Perazine) is officially classified as a Typical Antipsychotic and a phenothiazine derivative. It is not currently classified as a controlled substance, nor is it categorized as an opioid.


Q: What is the difference between Pernazinum and [similar drug name]?

Pernazinum belongs to the phenothiazine class of antipsychotics, which is a group defined by its specific chemical structure. While it is chemically related to some other phenothiazines, its unique side chain distinguishes it as a piperazine derivative within the class.


Q: Is there a generic version of Pernazinum available?

The active ingredient in Pernazinum, Perazine, is commonly manufactured and available as a generic medication. Generic versions typically offer the same active substance in various forms and strengths as the brand-name product.


Q: Does Pernazinum need to be stored in the refrigerator?

No, official regulations require that the medication be stored at room temperature, which is typically defined as between 15 C to 25 C. It should also be protected from light and moisture, and stored in a tightly closed container.


Q: Is it normal to feel slightly nauseous when first starting Pernazinum?

The official documentation lists nausea and vomiting among the known adverse reactions that may occur with the use of this medication. Gastrointestinal upset is a reported effect for medications of this type.


Q: Are there any known severe allergic reactions associated with Pernazinum?

The medicine is strictly forbidden (contraindicated) in patients with a known hypersensitivity to the phenothiazine class of drugs. Symptoms of severe allergic reactions, such as rash, severe swelling, or breathing difficulty, are documented to be serious and require prompt medical evaluation.


Q: Is Pernazinum an opioid?

No, Pernazinum is officially classified as a Typical Antipsychotic and a phenothiazine derivative. It is not an opioid or part of the opioid drug class.


Q: Does Pernazinum change or affect my mood?

The general purpose of the drug is described as stabilizing profoundly disturbed thought patterns and emotional states in patients with conditions like schizophrenia. Research studies monitor measurements related to overall clinical state and psychiatric scales, which may include components related to mood.


Q: Is Pernazinum often prescribed for anxiety?

The official indications for Pernazinum are limited to stabilizing disturbed thought and behavior in schizophrenia and related psychoses, and exploring severe agitated states. Anxiety is not listed as an approved indication in regulatory documents.


Q: Can Pernazinum interact with common pain relievers?

The medicine has documented interaction patterns that necessitate caution. Specific classes of over-the-counter pain relievers (analgesics) are known to interact with the drug and may require medical guidance due to the risk of potential additive central nervous system effects.


Q: Can I take Pernazinum if I have a liver condition?

Regulatory documents state that use requires restriction or caution for patients with hepatic impairment (liver function disorders). The required dose of the medicine must be reduced accordingly for this patient population.


Q: If I have a kidney issue, can I still use Pernazinum?

Official documents state that the use of Pernazinum requires restriction or caution for patients with renal (kidney) insufficiency. Specific guidance on dosage adjustments may be necessary.


Q: Do official documents mention any effects of Pernazinum on weight?

The official safety profile organizes adverse reactions by affected System-Organ Classes, which includes the Endocrine System. Weight change is listed as a potential adverse effect in regulatory documents for this class of drug.


Q: Can Pernazinum be taken on an empty stomach?

According to official prescribing principles for phenothiazines, the medicine can generally be taken without regard to food. This means that taking it on an empty stomach is not restricted.


Q: Does the packaging of Pernazinum contain lactose or gluten?

Official regulatory information for medications in tablet form specifies all inactive ingredients (excipients). This detailed information, which addresses components like lactose or gluten, is available in the complete regulatory product documents.


Q: Can Pernazinum be crushed or split?

The medicine is available as immediate-release tablets and an oral solution. The regulatory product information does not describe or support altering the tablet by crushing or splitting.


Q: What happens if I accidentally take more Pernazinum than described?

Official patient information on overexposure warns of serious symptoms that may include difficulty responding, fast or irregular heartbeat, coma, or seizures. This situation is documented to be serious and requires immediate evaluation.


Q: Do studies suggest Pernazinum is effective in children?

The medicine is generally approved for use in adults for its labeled indications and is not recommended for children under 12 years of age. Research evidence for this age group is insufficient, meaning results from the original trials apply only to the adult populations studied.


Q: What does the label say about using Pernazinum with other prescription drugs?

Official labeling documents a wide range of interaction patterns, including with drugs that cause central nervous system depression, anticholinergic drugs, and medicines that affect certain liver enzymes. A comprehensive list of these interactions is detailed in the full regulatory product information.


Q: Does Pernazinum require a prescription?

Yes, Pernazinum is classified as a prescription medication. It requires a valid prescription from a licensed healthcare provider for its use.


Q: What is the recommended age group for using Pernazinum?

The medicine is generally approved for use in adults for its labeled indications. It is not recommended or contraindicated for children under 12 years of age, and its use is restricted in older adults with dementia-related psychosis.


Q: Can elderly patients use Pernazinum?

Yes, but official guidelines require specific restrictions. For older adults, treatment must begin with a significantly reduced starting dose compared to younger adults. The medicine is absolutely forbidden in older adults with dementia-related psychosis due to increased mortality risk.


Q: Are there any foods or drinks I need to avoid while taking Pernazinum?

Official documents strictly prohibit combining the medication with alcohol. Beyond this restriction, the medication can generally be taken without regard to food. However, official information states that substances like tobacco smoking may affect how the drug is cleared from the body.

Advertisements

How should Pernazinum be stored and disposed of?

How to Store and Dispose of Pernazinum?

Official regulations require Pernazinum (Perazine) to be stored to maintain its quality and prevent degradation. The medicine should be kept at room temperature, typically defined as 15 C to 25 C. It is mandatory to protect the product from light and moisture and keep it in a tightly closed container.

Required Storage and Safety

Condition Requirement
Temperature 15 C to 25 C (Room Temperature)
Protection Keep protected from light, moisture, and heat.
Child Safety Must be kept out of the sight and reach of children

Disposal Instructions

Unused or expired Pernazinum must be disposed of according to official regulatory protocols. The preferred method is using a drug take-back program. If this is unavailable, the medicine can be mixed with an unappealing substance, sealed in a container, and placed in household trash. It is explicitly required to prevent the product from entering drains or the aquatic environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pernazinum found in:

A-Z Index: